Patient-specific QA using 4D Monte Carlo phase space predictions and EPID dosimetry

8th International Conference on 3D Radiation Dosimetry

Popescu, I.A.^1,2 ; Atwal, P.^1 ; Lobo, J.^2 ; Lucido, J.^3 ; McCurdy, B.M.C.^4

British Columbia Cancer Agency, Vancouver

BC, Canada^1

University of British Columbia, Vancouver

BC, Canada^2

University of Colorado School of Medicine, Denver

CO, United States^3

CancerCare Manitoba, University of Manitoba, Winnipeg

MB, Canada^4

关键词: Delivery techniques;    Direct response;    European Countries;    Fully automated;    In-vivo;    Monte Carlo predictions;    Patient specific;    Regulatory frameworks;   

Others  :  https://iopscience.iop.org/article/10.1088/1742-6596/573/1/012004/pdf
DOI  :  10.1088/1742-6596/573/1/012004

来源: IOP

【 摘 要 】

The goal of this review is to outline a solution for patient-specific QA of VMAT, IMRT, and other complex treatment delivery techniques. This solution has been developed in direct response to clinical needs, in order to allow our institution to offer VMAT to all patients who could potentially benefit from this advanced technique. To date, over 2500 VMAT patient plans and approximately 1000 IMRT patient plans have been verified by this method in Vancouver, while 40 other institutions worldwide have expressed interest in, or are already at various stages of implementing, this process. The addition of EPID in vivo dosimetry (i.e. data acquired during the patient treatment) and associated Monte Carlo predictions amounts to introducing a 'measurement component' in this QA process, which is currently mandated by the regulatory framework in some European countries, or for billing purposes in the USA. The fully automated, patient-specific, Monte Carlo based QA process described here is fast, maximally efficient in terms of departmental resources, and capable of simulating any plan in a single run, regardless of its complexity.